The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Immune drug developer Odyssey Therapeutics is gearing up for its second chance at an IPO, outlining terms for an offering that could raise $211 million or more.

    Updated 18 hours ago
  • Kailera employees celebrate while ringing the opening bell at Nasdaq.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc. / Vanja Savic
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.

    Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.

  • MRI Brain scan
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With $97M, Latus pursues a different kind of Huntington’s gene therapy

    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Celcuity strengthens case for ASCO-spotlighted breast cancer drug

    The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

  • Street signs for the intersection of Wall St. and Broad St., with the stripes of an American flag in the background.
    Image attribution tooltip
    Michael Santiago/Getty Images via Getty Images
    Image attribution tooltip
    IPO window

    Two biotechs raise a combined $556M in latest spurt of IPOs

    Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.

  • A micrograph of estrogen receptor staining in a breast cancer tumor sample.
    Image attribution tooltip
    Douglas Olivares via Getty Images
    Image attribution tooltip

    Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

    Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

    Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

  • Employees of biotechnology company UniQure work in a laboratory.
    Image attribution tooltip
    Courtesy of UniQure
    Image attribution tooltip

    UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

    News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Vaccines

    Moderna sees revenue bump from international COVID vaccine sales

    The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.

  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck still sees ‘compelling’ outlook for Terns leukemia drug

    Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    UCB’s buyout of Candid is the sector’s seventh acquisition in the last week, adding to a pace that’s turning 2026 into one of the most active years ever for biotech M&A.

    Updated May 4, 2026
  • A pill bottle for Eli Lilly's oral weight loss medication Foundayo
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip
    Obesity drugs

    Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

    A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.

  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    IPO window

    Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

    The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip

    Chiesi to buy KalVista in $1.9B deal for rare disease drug

    The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.

  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip
    Brain drug revival

    Teva nabs experimental Tourette drug in $700M Emalex buyout

    A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business. 

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    BeOne Medicines grabbed an option to acquire an antibody from HuaHui Health that acts on three known cancer targets: PD-1, CTLA-4 and VEGF.

    Updated May 1, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech

    Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.

  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer deals extend patent life for a top-selling rare disease drug

    Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam. 

  • A flag bearing the words Boehringer Ingelheim flaps in the breeze.
    Image attribution tooltip
    Courtesy of Boehringer Ingelheim
    Image attribution tooltip
    Obesity drugs

    Boehringer dual-acting obesity shot hits mark in Phase 3 trial

    Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Coultreon banks $125M to support testing of former Galapagos immune drug

    Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results

    Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.

  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Veradermics soars on positive data for baldness treatment

    The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.  

  • Intellia Therapeutics
    Image attribution tooltip
    Permission granted by Intellia Therapeutics
    Image attribution tooltip
    Gene editing

    Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder

    The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.

  • A man poses in a laboratory setting.
    Image attribution tooltip
    Permission granted by Ajax Therapeutics
    Image attribution tooltip

    Lilly to buy startup Ajax in bid for a better JAK drug

    Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.